Compounded GLP-1 medications powered a wave of telehealth weight-management clinics — and then the ground shifted. If you are launching or running a telehealth practice that touches semaglutide or tirzepatide, you need a clear, current picture of what is permitted in 2026 and how to prescribe compliantly. This article is educational information for clinicians and entrepreneurs; it is not legal or medical advice, and compounding law changes quickly, so verify specifics with counsel and your pharmacy partners.
The short answer
Compounded semaglutide and tirzepatide are not banned outright in 2026, but the easy-access shortage window is closed. The FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved on February 21, 2025. With the shortages over, pharmacies can no longer routinely compound copies of the commercial products. Compounding is now limited to legitimate, patient-specific clinical circumstances through appropriately licensed pharmacies.
What actually changed
During a declared shortage, 503A pharmacies were permitted to compound “essentially copies” of the branded drugs to meet demand. Once the FDA resolves a shortage, that allowance ends. The result:
- The “compound a copy for everyone” model is gone. You cannot base a clinic on routinely dispensing compounded versions simply because they are cheaper or more convenient.
- The patient-specific exception remains. A 503A pharmacy can still compound for an individual patient when a prescriber documents a clinical need the commercial product cannot meet.
- 503B outsourcing facilities face ongoing, evolving regulatory pressure and their own rules — a moving target worth watching closely.
When compounded GLP-1s are still permissible
The lawful pathway in 2026 centers on documented, patient-specific need. Common examples clinicians cite include:
- A strength or dose that differs from any commercially available presentation.
- A formulation that avoids an inactive ingredient the patient reacts to.
- Other individualized clinical circumstances the approved product cannot address.
The common thread: the prescriber must evaluate the patient, document why the commercial product does not meet that patient’s needs, and route the prescription to a state-licensed 503A compounding pharmacy. “It’s cheaper” is not a patient-specific clinical justification.
The elements of a compliant telehealth GLP-1 workflow
- A real consultation with a licensed prescriber who has evaluated the patient.
- A documented, patient-specific clinical need in the chart — not a template applied to everyone.
- Dispensing by a state-licensed 503A pharmacy operating within its compounding authority.
- Clear protocols for dosing, titration, monitoring, and adverse-event management.
- State-by-state awareness — some states layer additional weight-management and delegation rules on top of federal compounding law.
Clinics that treat these as paperwork will struggle; clinics that build them into standard operating procedure protect both patients and the business.
What this means for practitioners building a clinic
The compliant path forward for most telehealth practices is a hybrid, clinically grounded model: prescribe FDA-approved branded products where appropriate, reserve compounded formulations for genuine patient-specific needs, and document rigorously. That is a durable model. A clinic whose entire economic thesis depends on mass-compounding copies is exposed to the next regulatory turn.
Designing that workflow — the prescriber protocols, documentation standards, pharmacy relationships, and state-specific rules — is exactly the kind of infrastructure that trips up first-time clinic owners.
Frequently asked questions
Is compounded semaglutide legal in 2026?
It is not banned, but it is restricted. With the shortage resolved, 503A pharmacies can compound semaglutide only for individual patients with a documented, patient-specific clinical need — not as routine copies of the branded product.
Can I still prescribe compounded tirzepatide?
Yes, within the same patient-specific framework. The tirzepatide shortage was declared resolved in October 2024, so routine copying ended; individualized, documented compounding through a licensed 503A pharmacy remains the pathway.
What counts as a “patient-specific need”?
Circumstances the commercial product cannot meet — for example a non-standard dose or a formulation avoiding an inactive ingredient a patient reacts to. The prescriber must document the rationale in the chart.
What’s the difference between 503A and 503B here?
503A pharmacies compound for individual patients against a prescription; 503B outsourcing facilities compound at larger scale and operate under separate, evolving rules. Most patient-specific compounding runs through 503A.
Does telehealth change the compounding rules?
The compounding rules are the same, but telehealth adds licensure and consultation requirements: a genuine evaluation by a prescriber licensed in the patient’s state, proper documentation, and compliant dispensing.
Should I build my clinic around compounded GLP-1s?
A resilient clinic uses a hybrid model — approved products plus patient-specific compounding where justified — rather than depending on mass-compounding, which is vulnerable to regulatory change.
Build a clinic that stays compliant as the rules move
If you want a telehealth practice designed around durable, compliant workflows — not the last loophole — book a free info session to see how Clinic In A Box™ helps you build it the right way.
Educational information for clinicians and entrepreneurs only. Not legal, medical, or regulatory advice, and not a guarantee of any outcome. Compounding and telehealth rules change frequently and vary by state — verify current requirements with qualified counsel, your state boards, and your pharmacy partners before prescribing.